title: NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
authors: Sally
authors: S
authors: Doss
authors: Nicola
authors: N
authors: Hay
authors: Frances
authors: F
authors: Sutcliffe
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000592:standards / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000191:economics; D017410:Practice Guidelines as Topic; D011719:Pyrazines / Q000008:administration & dosage; D019057:Quality-Adjusted Life Years; D013222:State Medicine / Q000191:economics / Q000592:standards*; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib